Cadila Healthcare’s arm gets one observation for Ahmedabad plant from USFDA

27 Mar 2019 Evaluate

The US Food and Drug Administration (USFDA) has conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac Pharmaceuticals, the injectable onco manufacturing facility, located at Pharmez, Ahmedabad from March 18 to 26, 2019. The inspection concluded with one observation.

Alidac Pharmaceuticals is a 100% subsidiary of Cadila Healthcare. The company is addressing these observations and is confident of getting the product approval at the earliest.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

956.00 -8.40 (-0.87%)
26-Dec-2024 12:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.50
Dr. Reddys Lab 1346.40
Cipla 1480.25
Lupin 2174.90
Zydus Lifesciences 956.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.